CARTER BRUCE L A 4

What Happened

• Bruce L A Carter, a director of Enanta Pharmaceuticals, was granted a derivative award for 20,000 shares on March 11, 2026. The Form 4 reports the transaction as an award/acquisition (code A) with a reported price of $0.00 (derivative). No cash was listed as exchanged in the filing.

Key Details

• Transaction date: 2026-03-11; filing date: 2026-03-13.
• Transaction type/code: Award/Grant (A) of a derivative security; reported price $0.00.
• Shares/units granted: 20,000 (derivative award); total reported value: $0 (as listed on the Form 4).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Vesting: The award becomes exercisable in substantially equal monthly installments over one year beginning March 11, 2026; the final monthly installment vests no later than the nearest Nasdaq trading day before the 2027 annual meeting (footnote per filing).
• No indication in the excerpt that the shares were immediately sold or that a 10b5-1 plan or tax-withholding was used.

Context

• This is a typical equity compensation/retention grant to a director rather than an open-market purchase or sale. Such grants are common for aligning management/directors with shareholder interests but do not by themselves indicate an immediate bullish or bearish trading signal.
• The award vests over a year, so any potential future purchases or sales by the insider would occur later and would be reported separately.